BR112017010599A2 - análogos de ureia ligada substituída como moduladores sirtuin - Google Patents
análogos de ureia ligada substituída como moduladores sirtuinInfo
- Publication number
- BR112017010599A2 BR112017010599A2 BR112017010599A BR112017010599A BR112017010599A2 BR 112017010599 A2 BR112017010599 A2 BR 112017010599A2 BR 112017010599 A BR112017010599 A BR 112017010599A BR 112017010599 A BR112017010599 A BR 112017010599A BR 112017010599 A2 BR112017010599 A2 BR 112017010599A2
- Authority
- BR
- Brazil
- Prior art keywords
- diseases
- disorders
- substituted urea
- sirtuin modulators
- urea analogues
- Prior art date
Links
- 102000011990 Sirtuin Human genes 0.000 title abstract 3
- 108050002485 Sirtuin Proteins 0.000 title abstract 3
- 150000003672 ureas Chemical class 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010053567 Coagulopathies Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 230000032683 aging Effects 0.000 abstract 1
- 230000023555 blood coagulation Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000011010 flushing procedure Methods 0.000 abstract 1
- -1 for example Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002438 mitochondrial effect Effects 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000035882 stress Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462081916P | 2014-11-19 | 2014-11-19 | |
| PCT/IB2015/058980 WO2016079711A1 (en) | 2014-11-19 | 2015-11-19 | Substituted bridged urea analogs as sirtuin modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017010599A2 true BR112017010599A2 (pt) | 2017-12-26 |
Family
ID=54705247
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017010602A BR112017010602A2 (pt) | 2014-11-19 | 2015-11-19 | análogos de ureia ligados em ponte substituídos como moduladores de sirtuína |
| BR112017010599A BR112017010599A2 (pt) | 2014-11-19 | 2015-11-19 | análogos de ureia ligada substituída como moduladores sirtuin |
| BR112017010595-0A BR112017010595A2 (pt) | 2014-11-19 | 2015-11-19 | análogos de ureia com ligações por pontes substituídas como moduladores de sirtuína |
| BR112017010601A BR112017010601A2 (pt) | 2014-11-19 | 2015-11-19 | análogos de ureia substituídos em ponte como moduladores de sirtuínas |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017010602A BR112017010602A2 (pt) | 2014-11-19 | 2015-11-19 | análogos de ureia ligados em ponte substituídos como moduladores de sirtuína |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017010595-0A BR112017010595A2 (pt) | 2014-11-19 | 2015-11-19 | análogos de ureia com ligações por pontes substituídas como moduladores de sirtuína |
| BR112017010601A BR112017010601A2 (pt) | 2014-11-19 | 2015-11-19 | análogos de ureia substituídos em ponte como moduladores de sirtuínas |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US20190048016A1 (enExample) |
| EP (4) | EP3220918A1 (enExample) |
| JP (4) | JP2017534664A (enExample) |
| KR (4) | KR20170083135A (enExample) |
| CN (4) | CN107207521A (enExample) |
| AU (4) | AU2015348941A1 (enExample) |
| BR (4) | BR112017010602A2 (enExample) |
| CA (4) | CA2968027A1 (enExample) |
| CL (1) | CL2017001275A1 (enExample) |
| CO (1) | CO2017004994A2 (enExample) |
| CR (1) | CR20170209A (enExample) |
| DO (1) | DOP2017000123A (enExample) |
| EA (1) | EA201791074A1 (enExample) |
| ES (1) | ES2823748T3 (enExample) |
| IL (1) | IL252252A0 (enExample) |
| MX (1) | MX2017006658A (enExample) |
| PE (1) | PE20171257A1 (enExample) |
| PH (1) | PH12017500913A1 (enExample) |
| RU (3) | RU2017120855A (enExample) |
| SG (1) | SG11201703824QA (enExample) |
| WO (4) | WO2016079710A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10653782B2 (en) * | 2014-11-25 | 2020-05-19 | Nortwestern University | Retroviral particles expressing Sirt1 embedded within PPCN |
| CN108329388A (zh) * | 2018-01-18 | 2018-07-27 | 天津市湖滨盘古基因科学发展有限公司 | 一种人的沉默配型信息调节蛋白突变蛋白及其应用 |
| CN108707150B (zh) * | 2018-05-14 | 2021-04-16 | 江苏惠利生物科技有限公司 | 一种咪唑并吡嗪医药中间体的制备方法 |
| CN108395436B (zh) * | 2018-05-14 | 2021-01-12 | 鹤壁市人民医院 | 一种咪唑并吡嗪医药中间体的制备方法 |
| CN110478339A (zh) * | 2019-08-12 | 2019-11-22 | 昆明理工大学 | 紫铆因在制备靶向恢复突变p53构象药物中的应用 |
| EP4025566A1 (de) * | 2019-09-02 | 2022-07-13 | Merck Patent GmbH | Materialien für organische elektrolumineszenzvorrichtungen |
| JP7764372B2 (ja) * | 2019-11-19 | 2025-11-05 | ルピン・リミテッド | クロマン化合物を調製する方法 |
| EP4090654B1 (en) * | 2020-01-17 | 2025-07-09 | Lupin Limited | Methods, processes and intermediates for preparing chroman compounds |
| CN114890955A (zh) * | 2022-06-23 | 2022-08-12 | 江西瑞威尔生物科技有限公司 | 一种n取代吗啉类有机化合物的制备工艺 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4727064A (en) | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| WO2006094210A2 (en) * | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | Tetrahydroquinoxalinone sirtuin modulators |
| UA108596C2 (xx) | 2007-11-09 | 2015-05-25 | Інгібітори пептиддеформілази | |
| WO2011059839A1 (en) * | 2009-10-29 | 2011-05-19 | Sirtris Pharmaceuticals, Inc. | Bicyclic pyridines and analogs as sirtuin modulators |
| EP2790701A1 (en) * | 2011-12-12 | 2014-10-22 | SMB Innovation | Novel heterocyclic compounds useful in sirtuin binding and modulation |
| RU2015153061A (ru) * | 2013-05-13 | 2017-06-15 | ГЛЭКСОСМИТКЛАЙН ЭлЭлСи | Замещенные связанные мостиковой связью мочевинные аналоги в качестве модуляторов сиртуина |
-
2015
- 2015-11-19 CN CN201580073782.4A patent/CN107207521A/zh active Pending
- 2015-11-19 CA CA2968027A patent/CA2968027A1/en not_active Abandoned
- 2015-11-19 BR BR112017010602A patent/BR112017010602A2/pt not_active Application Discontinuation
- 2015-11-19 JP JP2017526950A patent/JP2017534664A/ja active Pending
- 2015-11-19 BR BR112017010599A patent/BR112017010599A2/pt not_active Application Discontinuation
- 2015-11-19 EP EP15804601.1A patent/EP3220918A1/en not_active Withdrawn
- 2015-11-19 EP EP15816522.5A patent/EP3221322A1/en not_active Withdrawn
- 2015-11-19 BR BR112017010595-0A patent/BR112017010595A2/pt not_active Application Discontinuation
- 2015-11-19 EP EP15801270.8A patent/EP3221316A1/en not_active Withdrawn
- 2015-11-19 SG SG11201703824QA patent/SG11201703824QA/en unknown
- 2015-11-19 MX MX2017006658A patent/MX2017006658A/es unknown
- 2015-11-19 US US15/527,851 patent/US20190048016A1/en not_active Abandoned
- 2015-11-19 US US15/527,581 patent/US10072011B2/en not_active Expired - Fee Related
- 2015-11-19 WO PCT/IB2015/058978 patent/WO2016079710A1/en not_active Ceased
- 2015-11-19 AU AU2015348941A patent/AU2015348941A1/en not_active Abandoned
- 2015-11-19 RU RU2017120855A patent/RU2017120855A/ru unknown
- 2015-11-19 KR KR1020177016280A patent/KR20170083135A/ko not_active Withdrawn
- 2015-11-19 PE PE2017000883A patent/PE20171257A1/es not_active Application Discontinuation
- 2015-11-19 EA EA201791074A patent/EA201791074A1/ru unknown
- 2015-11-19 JP JP2017526875A patent/JP2017534663A/ja not_active Withdrawn
- 2015-11-19 AU AU2015348942A patent/AU2015348942B2/en not_active Ceased
- 2015-11-19 AU AU2015348943A patent/AU2015348943A1/en not_active Abandoned
- 2015-11-19 JP JP2017526965A patent/JP2017534665A/ja active Pending
- 2015-11-19 RU RU2017120858A patent/RU2017120858A/ru unknown
- 2015-11-19 ES ES15801271T patent/ES2823748T3/es active Active
- 2015-11-19 US US15/527,941 patent/US20180319810A1/en not_active Abandoned
- 2015-11-19 CN CN201580073769.9A patent/CN107207520A/zh active Pending
- 2015-11-19 CN CN201580073897.3A patent/CN107207509B/zh not_active Expired - Fee Related
- 2015-11-19 WO PCT/IB2015/058977 patent/WO2016079709A1/en not_active Ceased
- 2015-11-19 JP JP2017526852A patent/JP6806679B2/ja not_active Expired - Fee Related
- 2015-11-19 BR BR112017010601A patent/BR112017010601A2/pt not_active Application Discontinuation
- 2015-11-19 WO PCT/IB2015/058980 patent/WO2016079711A1/en not_active Ceased
- 2015-11-19 RU RU2017120857A patent/RU2017120857A/ru unknown
- 2015-11-19 AU AU2015348944A patent/AU2015348944A1/en not_active Abandoned
- 2015-11-19 EP EP15801271.6A patent/EP3221317B1/en active Active
- 2015-11-19 CR CR20170209A patent/CR20170209A/es unknown
- 2015-11-19 CN CN201580073311.3A patent/CN107108627A/zh active Pending
- 2015-11-19 CA CA2968029A patent/CA2968029A1/en not_active Abandoned
- 2015-11-19 WO PCT/IB2015/058981 patent/WO2016079712A1/en not_active Ceased
- 2015-11-19 CA CA2968032A patent/CA2968032A1/en not_active Abandoned
- 2015-11-19 KR KR1020177016278A patent/KR20170083134A/ko not_active Withdrawn
- 2015-11-19 KR KR1020177016277A patent/KR20170083133A/ko not_active Withdrawn
- 2015-11-19 CA CA2968030A patent/CA2968030A1/en not_active Abandoned
- 2015-11-19 US US15/527,440 patent/US20170355705A1/en not_active Abandoned
- 2015-11-19 KR KR1020177016279A patent/KR20170087907A/ko not_active Withdrawn
-
2017
- 2017-05-11 IL IL252252A patent/IL252252A0/en unknown
- 2017-05-17 PH PH12017500913A patent/PH12017500913A1/en unknown
- 2017-05-18 DO DO2017000123A patent/DOP2017000123A/es unknown
- 2017-05-18 CL CL2017001275A patent/CL2017001275A1/es unknown
- 2017-05-19 CO CONC2017/0004994A patent/CO2017004994A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017010599A2 (pt) | análogos de ureia ligada substituída como moduladores sirtuin | |
| UY35391A (es) | Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-cianometil)-amidas sustituidas inhibidores de catepsina c | |
| BR112015028613A2 (pt) | análogos de uréia com ligações por pontes substituída como moduladores de sirtuína | |
| BR112013028666A2 (pt) | compostos de pirazolo sulfonamida tricícilos e métodos para fazer e usar o mesmo | |
| BR112014004560A2 (pt) | compostos e composições como inibidores de c-kit quinase | |
| BR112014004504A2 (pt) | "composto como inibidor de c-kit cinase, seu uso, composição farmacêutica, e medicamento para o tratamento de uma doença mediada por uma cinase" | |
| BR112014004319A2 (pt) | compostos e composições como inibidores de c-kit cinase | |
| BR112015028879A2 (pt) | derivados heterocíclicos | |
| BR112014004465A2 (pt) | compostos e composições como inibidores de pdgfr cinase | |
| ECSP13013048A (es) | Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores | |
| BR112014000240A2 (pt) | derivados de benzilamina como inibidores de calicreína plasmática | |
| BR112013001753A2 (pt) | método para preparar uma composição d einter-alfa-inibidor (iaip) eriquecida de plasma, solução aquosa de iaip, e, método para tratar uma doença ou distúrbio associado com disfunção de iaip e associado com atividadede protease de serina no plasma aumentada. | |
| ECSP13013068A (es) | Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace2 | |
| BR112017012377A2 (pt) | conjugados anticorpo-fármaco com inibidores de bcl-xl permeáveis à célula | |
| BR112014023384A2 (pt) | inibidores de bace de di-hidro-tiazina e di-hidro-oxazina espirocíclicos, e composições e usos dos mesmos | |
| BR112015016315A2 (pt) | fluoro-[1,3]oxazinas como inibidores de bace1 | |
| BR112015001419A8 (pt) | composto, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo | |
| BR112015019412A2 (pt) | inibidores de bace1 | |
| MX2016003486A (es) | Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades. | |
| BR112014003704A2 (pt) | moduladores ror gama | |
| BR112014000792A2 (pt) | compostos de piperidinila para uso como inibidores da tanquirase | |
| BR112017009647A2 (pt) | 2-amino-3,5-difluoro-3,6-dimetil-6-fenil-3,4,5,6-tetraidropiridinas como inibidoras da bace1 para tratar a doença de alzheimer | |
| BR112018005861A2 (pt) | derivados de ácido oleanólico modificado com c4 para a inibição de il-17 e outros usos | |
| BR112015019919A2 (pt) | compostos bicíclicos | |
| BR112022009710A2 (pt) | Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |